BeiGene, Ltd.: BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) and EUSA Pharma (UK), Ltd. today announced that the China National Medical Products Administration (NMPA) has approved SYLVANT(siltuximab for injection) for
Source: finanznachrichten.de